Compare MetLife Inc. Common Stock (MET) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MetLife Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? MetLife Inc. Common Stock trades at $102.41 (market cap $63.96B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: MetLife Inc. Common Stock and Natera Inc. Common Stock are close in size by market cap, and MetLife Inc. Common Stock pays a 2.35% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MetLife Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| MET | NTRA | |
|---|---|---|
Market Cap | $63.96B | $57.03B |
Volume | 3,016,459 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $100.65 | $425.64 |
52-Week Low | $67.70 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $84.89B | $56.18B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MetLife (MET) trades at $100.65, up 0.48% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with a P/E of 19.28 and a net income margin of 4.66%. Recent news highlights a declared dividend of $0.59 per share and upcoming Q3 2026 results.
The outlook for MET is positive, driven by earnings momentum and a favorable interest rate environment for insurers. Key risks include investment income volatility and competitive pressures. With a consensus price target of $108.25 and no sell ratings, Wall Street sentiment remains bullish, though the stock's RSI suggests potential near-term overbought conditions.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MetLife Inc. Common Stock
MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
